Literature DB >> 20093036

Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues.

Belinda Strydom1, Sarel F Malan, Neal Castagnoli, Jacobus J Bergh, Jacobus P Petzer.   

Abstract

Based on recent reports that several (E)-8-styrylcaffeinyl analogues are potent reversible inhibitors of monoamine oxidase B (MAO-B), a series of 8-benzyloxycaffeinyl analogues were synthesized and evaluated as inhibitors of baboon liver MAO-B and recombinant human MAO-A and -B. The 8-benzyloxycaffeinyl analogues were found to inhibit reversibly both MAO isoforms with enzyme-inhibitor dissociation constants (K(i) values) ranging from 0.14 to 1.30 microM for the inhibition of human MAO-A, and 0.023-0.59 microM for the inhibition of human MAO-B. The most potent MAO-A inhibitor was 8-(3-methylbenzyloxy)caffeine while 8-(3-bromobenzyloxy)caffeine was the most potent MAO-B inhibitor. The analogues inhibited human and baboon MAO-B with similar potencies. A quantitative structure-activity relationship (QSAR) study indicated that the MAO-B inhibition potencies of the 8-benzyloxycaffeinyl analogues are dependent on the Hansch lipophilicity (pi) and Hammett electronic (sigma) constants of the substituents at C-3 of the benzyloxy ring. Electron-withdrawing substituents with a high degree of lipophilicity enhance inhibition potency. These results are discussed with reference to possible binding orientations of the inhibitors within the active site cavities of MAO-A and -B. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093036     DOI: 10.1016/j.bmc.2009.12.064

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

Review 1.  Predicting monoamine oxidase inhibitory activity through ligand-based models.

Authors:  Santiago Vilar; Giulio Ferino; Elias Quezada; Lourdes Santana; Carol Friedman
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site.

Authors:  Rati K P Tripathi; Vishnu M Sasi; Sukesh K Gupta; Sairam Krishnamurthy; Senthil R Ayyannan
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

3.  Effect of some pyrimidine compounds on rat brain monoamine oxidase-B in vitro.

Authors:  Nadia Z Shaban; Mamdouh S Masoud; Mai A Mawlawi; Doaa Awad; Omayma M Sadek
Journal:  J Physiol Biochem       Date:  2012-03-31       Impact factor: 4.158

4.  Assay of MAO Inhibition by Chromatographic Techniques (HPLC/HPLC-MS).

Authors:  Tomás Herraiz
Journal:  Methods Mol Biol       Date:  2023

5.  2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.

Authors:  Lesetja J Legoabe; Anél Petzer; Jacobus P Petzer
Journal:  Drug Des Devel Ther       Date:  2015-07-15       Impact factor: 4.162

6.  3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors.

Authors:  Priyanka Dhiman; Neelam Malik; Anurag Khatkar
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

7.  Quantitative Structure-Neurotoxicity Assessment and In Vitro Evaluation of Neuroprotective and MAO-B Inhibitory Activities of Series N'-substituted 3-(1,3,7-trimethyl-xanthin-8-ylthio)propanehydrazides.

Authors:  Magdalena Kondeva-Burdina; Javor Mitkov; Iva Valkova; Lily Peikova; Maya Georgieva; Alexander Zlatkov
Journal:  Molecules       Date:  2022-08-20       Impact factor: 4.927

8.  3-Coumaranone derivatives as inhibitors of monoamine oxidase.

Authors:  Adriaan S Van Dyk; Jacobus P Petzer; Anél Petzer; Lesetja J Legoabe
Journal:  Drug Des Devel Ther       Date:  2015-10-03       Impact factor: 4.162

9.  The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.

Authors:  Stephanus J Cloete; Clarina I N'Da; Lesetja J Legoabe; Anél Petzer; Jacobus P Petzer
Journal:  Mol Divers       Date:  2020-09-24       Impact factor: 2.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.